Pacira BioSciences, Inc. (PCRX)

Market Cap	1.08B
Revenue (ttm)	716.79M
Net Income (ttm)	21.44M
Shares Out	43.02M
EPS (ttm)	0.47
PE Ratio	52.07
Forward PE	7.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,792
Open	24.50
Previous Close	24.46
Day's Range	24.50 - 25.01
52-Week Range	18.17 - 27.64
Beta	0.24
Analysts	Strong Buy
Price Target	32.86 (+31.44%)
Earnings Date	Nov 6, 2025

About PCRX

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled dos...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2011
• Employees: 790
• Stock Exchange: NASDAQ
• Ticker Symbol: PCRX
• Website: https://www.pacira.com

Analyst Summary

According to 7 analysts, the average rating for PCRX stock is "Strong Buy." The 12-month stock price target is $32.86, which is an increase of 31.44% from the latest price.

Price Target

$32.86

(31.44% upside)

Analyst Consensus: Strong Buy